Trial Profile
Aprepitant for the treatment of refractory pruritus in patients with primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Aug 2015
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- 24 Aug 2015 New trial record